These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 16896073)

  • 41. Current status and progress of prepandemic and pandemic influenza vaccine development.
    Leroux-Roels I; Leroux-Roels G
    Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
    Sun X; Belser JA; Pulit-Penaloza JA; Creager HM; Guo Z; Jefferson SN; Liu F; York IA; Stevens J; Maines TR; Jernigan DB; Katz JM; Levine MZ; Tumpey TM
    Virology; 2017 Aug; 508():164-169. PubMed ID: 28554058
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ethical considerations for NIH funded highly transmissible H5N1.
    Salhanick M
    Pharos Alpha Omega Alpha Honor Med Soc; 2013; 76(1):6-9. PubMed ID: 23444692
    [No Abstract]   [Full Text] [Related]  

  • 44. Pre- or post-pandemic influenza vaccine?
    Osterhaus AD
    Vaccine; 2007 Jun; 25(27):4983-4. PubMed ID: 17555851
    [No Abstract]   [Full Text] [Related]  

  • 45. Pandemic influenza vaccine development: time is of the essence.
    Cox RJ; Brokstad KA; Haaheim LR
    Expert Rev Vaccines; 2006 Oct; 5(5):603-6. PubMed ID: 17181432
    [No Abstract]   [Full Text] [Related]  

  • 46. Prepandemic influenza vaccines.
    Bermejo-Martin JF; Tenorio-Abreu A; Vega T; Eiros JM; Castrodeza J; de Lejarazu RO
    Lancet Infect Dis; 2009 Apr; 9(4):206-7; author reply 207-9. PubMed ID: 19324290
    [No Abstract]   [Full Text] [Related]  

  • 47. Aflunov(®): a prepandemic influenza vaccine.
    Gasparini R; Amicizia D; Lai PL; Panatto D
    Expert Rev Vaccines; 2012 Feb; 11(2):145-57. PubMed ID: 22309663
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pandemic influenza: using evidence on vaccines and antivirals for clinical decisions and policy making.
    Granados A; Goodman C; Eklund L
    Eur Respir J; 2006 Apr; 27(4):661-3. PubMed ID: 16585070
    [No Abstract]   [Full Text] [Related]  

  • 49. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Strategic analysis on responding human avian flu and flu pandemic in China.
    Zeng G
    Biomed Environ Sci; 2006 Apr; 19(2):158-61. PubMed ID: 16827190
    [No Abstract]   [Full Text] [Related]  

  • 51. Federal government prepares for avian flu epidemic.
    Duvall D
    Consult Pharm; 2006 Apr; 21(4):345-6. PubMed ID: 16676450
    [No Abstract]   [Full Text] [Related]  

  • 52. Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms.
    Luke CJ; Subbarao K
    Expert Rev Vaccines; 2014 Jul; 13(7):873-83. PubMed ID: 24855993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Avian influenza. Preaching against the pandemic.
    Enserink M
    Science; 2005 Oct; 310(5747):429. PubMed ID: 16239456
    [No Abstract]   [Full Text] [Related]  

  • 54. Vaccines for seasonal and pandemic influenza.
    Nichol KL; Treanor JJ
    J Infect Dis; 2006 Nov; 194 Suppl 2():S111-8. PubMed ID: 17163383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adults.
    Song JY; Choi MJ; Noh JY; Choi WS; Cheong HJ; Wie SH; Lee JS; Woo GJ; Lee SH; Kim WJ
    Hum Vaccin Immunother; 2017 May; 13(5):1190-1197. PubMed ID: 27996363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.
    Leroux-Roels G
    Expert Opin Biol Ther; 2009 Aug; 9(8):1057-71. PubMed ID: 19555313
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical evaluation of vaccines for pandemic influenza H5N1.
    Pareek M; Stephenson I
    Br J Hosp Med (Lond); 2007 Feb; 68(2):80-4. PubMed ID: 17370705
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.
    Chada KE; Forshee R; Golding H; Anderson S; Yang H
    Vaccine; 2017 May; 35(24):3162-3170. PubMed ID: 28483200
    [TBL] [Abstract][Full Text] [Related]  

  • 59. United States issues draft guidance for pandemic flu vaccination.
    Traynor K
    Am J Health Syst Pharm; 2007 Dec; 64(23):2412-4. PubMed ID: 18029943
    [No Abstract]   [Full Text] [Related]  

  • 60. Development of vaccines against influenza A virus (H5N1).
    Li WC; Huang YC
    Chang Gung Med J; 2007; 30(4):294-304. PubMed ID: 17939259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.